The identification of vulnerable coronary artery atherosclerotic plaques offers the prospect of either localized or systematic therapeutic targeting in order to prevent myocardial infarction. Molecular imaging of atherosclerosis adds to morphological imaging by focusing on the immunobiology hidden in and behind the endothelium and therefore may be able to improve the identification of prospective culprit lesions. Our focus has been on identifying arterial accumulation of oxidized low-density lipoprotein (oxLDL) by exploiting advances in knowledge of vascular pathobiology. Here, we reflect on our work developing near-infrared fluorescence imaging of oxLDL using LO1, a monoclonal autoantibody generated in our laboratory. We detail progress to date and discuss our vision on taking the work through the early translational pipeline toward a multitargeted approach in imaging rupture-prone atherosclerotic plaques. Ultimately, molecular imaging of coronary arteries should be able to assess the regional risk that is specific to a lesion, which can then be used in concert with global risk factors to personalize the therapeutic strategy for patients in a way that goes beyond generalized population-based therapies.

中文翻译：

---

制定动脉粥样硬化氧化低密度脂蛋白介入分子成像策略。

易损冠状动脉粥样硬化斑块的鉴定为预防心肌梗塞提供了局部或系统治疗靶向的前景。动脉粥样硬化的分子成像通过关注隐藏在内皮内部和背后的免疫生物学增加了形态学成像，因此可能能够改善对潜在罪魁祸首病变的识别。我们的重点是通过利用血管病理学知识的进步来识别氧化低密度脂蛋白 (oxLDL) 的动脉积聚。在这里，我们回顾了我们使用 LO1 开发 oxLDL 近红外荧光成像的工作，LO1 是我们实验室产生的一种单克隆自身抗体。我们详细介绍了迄今为止的进展，并讨论了我们对通过早期转化管道开展工作的愿景，以采用多靶点方法对易破裂的动脉粥样硬化斑块进行成像。最终，冠状动脉的分子成像应该能够评估特定于病变的区域风险，然后可以与全球风险因素一起使用，以超越基于一般人群的方式为患者制定个性化治疗策略疗法。